KIR3DL1 and acute myeloid leukemia: For example, the fully human IgG4 mAb lirilumab, directed against a common epitope shared by KIR2D, has been shown to block the KIR/KIR-L interaction and increase NK cell-mediated killing of AML blasts both in vitro and in vivo [215].